<DOC>
	<DOCNO>NCT01514851</DOCNO>
	<brief_summary>To assess effect reduction serum phosphate safety BAY77-1931 ( Lanthanum Carbonate ) patient hyperphosphatemia undergoing hemodialysis randomize , double-blind , parallel group study comparison Calcium carbonate .</brief_summary>
	<brief_title>Phase III Double-blind Comparative Study BAY77-1931 ( Lanthanum Carbonate ) With Calcium Carbonate</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Predialysis serum phosphate level : ≧5.6 mg/dL &lt; 11.0 mg/dL 1 week initiation washout period . Outpatient Undergoing hemodialysis three time per week least previous 3 consecutive month Predialysis serum phosphate level ≧10.0 mg/dL start washout period ≧11.0 mg/dL 1 week Corrected serum calcium level &lt; 7.0 mg/dL ≧11.0 mg/dL start washout period and/or 1 week Serum intact PTH ( Parathyroid ) ≧1000 pg/mL start washout period Pregnant woman , lactate mother Significant gastrointestinal disorder include know acute peptic ulcer Liver dysfunction History cardiovascular cerebrovascular disease Requiring treatment hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hyperphosphatemia ESRD ( End Stage Renal Disease ) patient dialysis</keyword>
</DOC>